[HTML][HTML] Hypoxia signaling in human health and diseases: implications and prospects for therapeutics

Z Luo, M Tian, G Yang, Q Tan, Y Chen, G Li… - Signal transduction and …, 2022 - nature.com
Molecular oxygen (O2) is essential for most biological reactions in mammalian cells. When
the intracellular oxygen content decreases, it is called hypoxia. The process of hypoxia is …

[HTML][HTML] Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review

Y Sakr, M Giovini, M Leone, G Pizzilli, A Kortgen… - Annals of intensive …, 2020 - Springer
Background Preliminary reports have described significant procoagulant events in patients
with coronavirus disease-2019 (COVID-19), including life-threatening pulmonary embolism …

Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney

H Bayır, SJ Dixon, YY Tyurina, JA Kellum… - Nature Reviews …, 2023 - nature.com
Ferroptosis is a mechanism of regulated necrotic cell death characterized by iron-
dependent, lipid peroxidation-driven membrane destruction that can be inhibited by …

[HTML][HTML] PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia

Y Xie, X Shi, K Sheng, G Han, W Li… - Molecular …, 2019 - spandidos-publications.com
The purpose of this review is to summarize the research progress of PI3K/Akt signaling
pathway in erythropoiesis and glycolysis. Phosphatidylinositol‑4, 5‑bisphosphate 3‑kinase …

Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study

S Fishbane, MA El-Shahawy… - Journal of the …, 2021 - journals.lww.com
Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …

[HTML][HTML] Von Hippel–Lindau disease: Insights into oxygen sensing, protein degradation, and cancer

WG Kaelin - The Journal of Clinical Investigation, 2022 - Am Soc Clin Investig
Germline loss-of-function mutations of the VHL tumor suppressor gene cause von Hippel–
Lindau disease, which is associated with an increased risk of hemangioblastomas, clear cell …

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)

J Barratt, B Andric, A Tataradze… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …

[HTML][HTML] Burden of anemia in chronic kidney disease: beyond erythropoietin

RM Hanna, E Streja, K Kalantar-Zadeh - Advances in therapy, 2021 - Springer
Anemia is a frequent comorbidity of chronic kidney disease (CKD) and is associated with a
considerable burden because of decreased patient health-related quality of life and …

[HTML][HTML] Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open …

B Csiky, M Schömig, C Esposito, J Barratt, M Reusch… - Advances in …, 2021 - Springer
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

[HTML][HTML] Hypoxia and chronic kidney disease

B Wang, ZL Li, YL Zhang, Y Wen, YM Gao, BC Liu - EBioMedicine, 2022 - thelancet.com
Hypoxia is an inherent pathophysiological characteristic of chronic kidney disease (CKD),
which is closely associated with the development of renal inflammation and fibrosis, as well …